ALT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

560.00

-88.8%

-0.243

-26.41%

830.00

-83.4%

-0.275

+5.77%

830.00

-83.4%

-0.287

+6.17%

Estimates Revision

The market is revising Upward the revenue expectations for Altimmune, Inc. (ALT) for FY2025, with the revenue forecasts being adjusted by 16.82% over the past three months. During the same period, the stock price has changed by 2.55%.

Revenue Estimates for FY2025

Revise Upward

+16.82%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+2.55%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

12.00

Averages

13.00

High

14.00

Current: 0.000

Low

12.00

Averages

13.00

High

14.00

Citizens JMP

Jonathan Wolleben

Outperform

downgrade

$15 -> $14

2025-11-07

Reason

Citizens JMP

Jonathan Wolleben

Price Target

$15 -> $14

2025-11-07

downgrade

Outperform

Reason

Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on Altimmune to $14 from $15 and keeps an Outperform rating on the shares. The firm says it looks forward to the oral late-breaking presentation of pemvidutide's Phase 2b data at the Liver Meeting with 48-week data on track for this quarter.

UBS

Buy

downgrade

$26 -> $24

2025-08-13

Reason

UBS

Price Target

$26 -> $24

2025-08-13

downgrade

Buy

Reason

UBS lowered the firm's price target on Altimmune to $24 from $26 and keeps a Buy rating on the shares. Despite the IMPACT Phase 2b trial setback, UBS still sees a sizeable opportunity for pemvidutide in nonalcoholic steatohepatitis, the analyst tells investors in a research note.

Goldman Sachs

initiated

2025-07-10

Reason

Goldman Sachs

Price Target

2025-07-10

initiated

Reason

Goldman Sachs resumed coverage of Altimmune with a Sell rating and $1 price target, representing 79% downside. The company's data to-date has not demonstrated a meaningfully differentiated profile for pemvidutide in either obesity or metabolic dysfunction associated steatohepatitis, the analyst tells investors in a research note. The firm sees challenges for Altimmune to execute the full clinical development program required to bring pemvidutide to market.

Citizens JMP

Outperform

NULL

downgrade

$25 -> $15

2025-07-10

Reason

Citizens JMP

Price Target

$25 -> $15

2025-07-10

downgrade

Outperform

NULL

Reason

Citizens JMP lowered the firm's price target on Altimmune to $15 from $25 and keeps an Outperform rating on the shares. Pemvidutide is still a competitive MASH candidate, but its path forward has become more difficult, the analyst tells investors in a research note. The firm thinks pemvidutide will hit both fibrosis and MASH resolution in Phase 3, but says Altimmune needs additional capital to get through the pivotal MASH program, which will now be the overhang on the stock.

Jefferies

Buy

maintain

$28

2025-06-27

Reason

Jefferies

Price Target

$28

2025-06-27

maintain

Buy

Reason

Jefferies believes Altimmune stock dropping 50% after the company announced results from its IMPACT study is overkill, as data met the firm's most likely scenario. Jefferies sees pemvidutide as a viable/safe drug uniquely positioned in MASH as the first incretin to hit statistical significance on histology at 24 weeks with potential to deepen with time and thinks these factors differentiate the drug from the fibroblast growth factor 21 class, the firm told investors in a research note. Jefferies added that the company can take meaningful share in the growing MASH market if successful. The firm reiterated a Buy rating and $28 price target on shares.

H.C. Wainwright

Patrick Trucchio

Buy

maintain

$12

2025-06-26

Reason

H.C. Wainwright

Patrick Trucchio

Price Target

$12

2025-06-26

maintain

Buy

Reason

H.C. Wainwright analyst Patrick Trucchio says the selloff in shares of Altimmune on the IMPACT readout appears overdone. The company announced positive topline data from the 24-week Phase 2b IMPACT trial evaluating pemvidutide in metabolic dysfunction-associated steatohepatitis, the analyst tells investors in a research note. While fibrosis improvement without worsening of MASH was observed in 31.8% and 34.5% of patients in the 1.2 mg and 1.8 mg arms, respectively, compared to 25.9% for placebo, these differences did not reach statistical significance, adds H.C. Wainwright. However, the firm says AI-based fibrosis reads and non-invasive tests showed significant improvements, "reinforcing evidence of anti-fibrotic activity." Wainwright believes these data support advancement to Phase 3 and strengthen the case for pemvidutide as a potential best-in-class therapy. It reiterates a Buy rating on Altimmune with a $12 price target. The stock in midday trading is down 55%, or $4.21, to $3.51.

Valuation Metrics

The current forward P/E ratio for Altimmune Inc (ALT.O) is -3.14, compared to its 5-year average forward P/E of -5.69. For a more detailed relative valuation and DCF analysis to assess Altimmune Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.69

Current PE

-3.14

Overvalued PE

-2.70

Undervalued PE

-8.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.75

Current EV/EBITDA

-1.42

Overvalued EV/EBITDA

-0.90

Undervalued EV/EBITDA

-4.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

29319.91

Current PS

118142.51

Overvalued PS

84026.41

Undervalued PS

-25386.60

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ALT News & Events

Events Timeline

No data

News

3.5

01-06Globenewswire

Altia Powers Cadillac Escalade IQ to Win 2026 MotorTrend SUV of the Year

9.0

01-06NASDAQ.COM

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide, Significantly Improving Liver Health

9.0

01-05Benzinga

Altimmune (ALT) Receives FDA Breakthrough Therapy Designation for Pemvidutide, Shares Surge 16.9%

People Also Watch

Frequently Asked Questions

What is Altimmune Inc (ALT) stock price today?

The current price of ALT is 4.02 USD — it has decreased -1.47 % in the last trading day.

What is Altimmune Inc (ALT)'s business?

Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

What is the price predicton of ALT Stock?

What is Altimmune Inc (ALT)'s revenue for the last quarter?

Altimmune Inc revenue for the last quarter amounts to 5.00K USD, decreased 0.00 % YoY.

What is Altimmune Inc (ALT)'s earnings per share (EPS) for the last quarter?

Altimmune Inc. EPS for the last quarter amounts to -0.21 USD, decreased -34.38 % YoY.

What changes have occurred in the market's expectations for Altimmune Inc (ALT)'s fundamentals?

How many employees does Altimmune Inc (ALT). have?

Altimmune Inc (ALT) has 59 emplpoyees as of January 10 2026.

What is Altimmune Inc (ALT) market cap?

Today ALT has the market capitalization of 419.46M USD.